Cargando…

Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer

Triple-negative breast cancers (TNBC) lack estrogen and progesterone receptors and HER2 amplification, and are resistant to therapies that target these receptors. Tumors from TNBC patients are heterogeneous based on genetic variations, tumor histology, and clinical outcomes. We used high throughput...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiu, Alec M., Mitra, Mithun, Boymoushakian, Lari, Coller, Hilary A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081411/ https://www.ncbi.nlm.nih.gov/pubmed/30087365 http://dx.doi.org/10.1038/s41598-018-29992-5

Ejemplares similares

Intron retention is a robust marker of intertumoral heterogeneity in pancreatic ductal adenocarcinoma
por: Tan, Daniel J., et al.
Publicado: (2020)

Pan-cancer landscape of epigenetic factor expression predicts tumor outcome
por: Cheng, Michael W., et al.
Publicado: (2023)

Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer
por: Jiang, Lin, et al.
Publicado: (2022)

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
por: Bareche, Y, et al.
Publicado: (2018)

Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
por: Kudelova, Eva, et al.
Publicado: (2022)

Editorial: Triple-negative breast cancer: Heterogeneity, tumor microenvironment and targeted therapy
por: Deng, Xiyun, et al.
Publicado: (2022)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data
por: Raju, Rajesh, et al.
Publicado: (2014)

Molecular heterogeneity in adjacent cells in triple-negative breast cancer
por: Huebschman, Michael L, et al.
Publicado: (2015)

Heterogeneity at the invasion front of triple negative breast cancer cells
por: Aw Yong, Koh Meng, et al.
Publicado: (2020)

Evaluation of triple negative breast cancer with heterogeneous immune infiltration
por: Quintana, Ángela, et al.
Publicado: (2023)

Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
por: Bareche, Yacine, et al.
Publicado: (2019)

Unraveling Heterogeneity of Tumor Cells and Microenvironment and Its Clinical Implications for Triple Negative Breast Cancer
por: Jiang, Ke, et al.
Publicado: (2021)

Integrating Genomic Information with Tumor-Immune Microenvironment in Triple-Negative Breast Cancer
por: Otohinoyi, David, et al.
Publicado: (2022)

Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers
por: Wang, Lei, et al.
Publicado: (2020)

Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer
por: Kilmartin, Darren, et al.
Publicado: (2021)

High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer
por: Gupta, Nidhi, et al.
Publicado: (2017)

LncRNA-Based Classification of Triple Negative Breast Cancer Revealed Inherent Tumor Heterogeneity and Vulnerabilities
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2022)

MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
por: Doha, Zinab O., et al.
Publicado: (2023)

Is There a Histone Code for Cellular Quiescence?
por: Bonitto, Kenya, et al.
Publicado: (2021)

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
por: Jiang, Tingting, et al.
Publicado: (2016)

Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness
por: Mahmoud, Rinad, et al.
Publicado: (2022)

Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability
por: Ahn, Soomin, et al.
Publicado: (2021)

Phenotypic Heterogeneity of Triple-Negative Breast Cancer Mediated by Epithelial–Mesenchymal Plasticity
por: Kvokačková, Barbora, et al.
Publicado: (2021)

Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
por: Asleh, Karama, et al.
Publicado: (2022)

The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer
por: Fan, Yiqi, et al.
Publicado: (2022)

An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer
por: Ryall, Karen A, et al.
Publicado: (2015)

Integrated analysis of differentially expressed genes and pathways in triple-negative breast cancer
por: Peng, Cancan, et al.
Publicado: (2017)

Integrated analysis reveals the molecular features of fibrosis in triple-negative breast cancer
por: Ding, Jia-Han, et al.
Publicado: (2022)

Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer
por: Yuan, Yinyin
Publicado: (2015)

Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation
por: Romero-Cordoba, Sandra, et al.
Publicado: (2019)

Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
por: Li, Ming, et al.
Publicado: (2018)

Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
por: Loizides, Sotiris, et al.
Publicado: (2023)

Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis
por: He, Jinsong, et al.
Publicado: (2015)

Identification of Key Genes and Pathways in Triple-Negative Breast Cancer by Integrated Bioinformatics Analysis
por: Dong, Pengzhi, et al.
Publicado: (2018)

Integrative Analysis Reveals Subtype-Specific Regulatory Determinants in Triple Negative Breast Cancer
por: Huang, Shujun, et al.
Publicado: (2019)

Integrated bioinformatic analysis of potential biomarkers of poor prognosis in triple-negative breast cancer
por: Bissanum, Rassanee, et al.
Publicado: (2022)

An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
por: Cheng, Shao-Xian, et al.
Publicado: (2023)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_uppvsqaco8ptt7f3tm8vrdttc6